Chen Qianqian, Shang Xingchen, Yuan Meng, Liang Lining, Zhong Xia
Departments of aEmergency bBreast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Coron Artery Dis. 2017 Jan;28(1):44-51. doi: 10.1097/MCA.0000000000000435.
An association between coronary artery disease (CAD) and serum omentin-1 was recently identified. The aim of the present study was to investigate the effect of atorvastatin on serum levels of omentin-1 in patients with CAD.
One-hundred and ninety-eight patients with CAD were divided into two groups: those with acute coronary syndrome (ACS) and those with stable angina pectoris (SAP). All patients were randomized to receive atorvastatin therapy at a dose of either 20 or 40 mg/day for 12 weeks. Serum omentin-1 levels and other parameters were determined at baseline and at the end of the study.
Atorvastatin at 20 and 40 mg/day increased serum omentin-1 levels in patients with ACS (20 mg, P=0.007; 40 mg, P<0.001) and in those with SAP (20 mg, P=0.017; 40 mg, P<0.001). Atorvastatin at 40 mg induced greater changes in serum omentin-1 levels compared with 20 mg atorvastatin in both the ACS group (P=0.003) and the SAP group (P=0.012). The increments of serum omentin-1 levels with atorvastatin administration inversely correlated with changes in LDL cholesterol (r=-0.145, P=0.041), interleukin-6 (r=-0.162, P=0.023), and high-sensitivity C-reactive protein (r=-0.185, P=0.009) in patients with CAD. Furthermore, changes in LDL cholesterol (β=-0.158, P=0.027) and interleukin-6 (β=-0.154, P=0.044) remained independent determinants of omentin-1 alterations in standard multiple regression analysis (R=0.122, P=0.006) after adjusting for age, sex, smoking, family history of CAD, and BMI in patients with CAD.
Atorvastatin increased serum omentin-1 concentrations in patients with CAD in a dose-dependent manner.
最近发现冠状动脉疾病（CAD）与血清网膜素-1之间存在关联。本研究旨在探讨阿托伐他汀对CAD患者血清网膜素-1水平的影响。
198例CAD患者分为两组：急性冠状动脉综合征（ACS）组和稳定型心绞痛（SAP）组。所有患者随机接受阿托伐他汀治疗，剂量为20或40mg/天，持续12周。在基线和研究结束时测定血清网膜素-1水平及其他参数。
20mg/天和40mg/天的阿托伐他汀均可提高ACS患者（20mg，P = 0.007；40mg，P < 0.001）和SAP患者（20mg，P = 0.017；40mg，P < 0.001）的血清网膜素-1水平。在ACS组（P = 0.003）和SAP组（P = 0.012）中，4mg阿托伐他汀引起的血清网膜素-1水平变化比20mg阿托伐他汀更大。CAD患者服用阿托伐他汀后血清网膜素-1水平的升高与低密度脂蛋白胆固醇（LDL-C）（r = -0.145，P = 0.041）、白细胞介素-6（IL-6）（r = -0.162，P = 0.023）和高敏C反应蛋白（hs-CRP）（r = -0.185，P = 0.009）的变化呈负相关。此外，在对CAD患者的年龄、性别、吸烟、CAD家族史和体重指数进行校正后的标准多元回归分析（R = 0.122，P = 0.006）中，LDL-C（β = -0.158，P = 0.027）和IL-6（β = -0.154，P = 0.044）的变化仍然是网膜素-1改变的独立决定因素。
阿托伐他汀以剂量依赖的方式增加CAD患者的血清网膜素-1浓度。
